SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)<sup>1</sup&...
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
Springer Nature
2021
|
| _version_ | 1826307521820753920 |
|---|---|
| author | Mlcochova, P Kemp, SA Dhar, MS Papa, G Meng, B Ferreira, IATM Datir, R Collier, DA Albecka, A Singh, S Pandey, R Brown, J Zhou, J Goonawardane, N Mishra, S Whittaker, C Mellan, T Marwal, R Datta, M Sengupta, S Ponnusamy, K Radhakrishnan, VS Abdullahi, A Charles, O Chattopadhyay, P Devi, P Caputo, D Peacock, T Wattal, C Goel, N Satwik, A Vaishya, R Agarwal, M Mavousian, A Lee, JH Bassi, J Silacci-Fegni, C Saliba, C Pinto, D Irie, T Yoshida, I Hamilton, WL Sato, K Bhatt, S Flaxman, S James, LC Corti, D Baker, S |
| author2 | Indian SARS-CoV-2 Genomics Consortium (INSACOG) |
| author_facet | Indian SARS-CoV-2 Genomics Consortium (INSACOG) Mlcochova, P Kemp, SA Dhar, MS Papa, G Meng, B Ferreira, IATM Datir, R Collier, DA Albecka, A Singh, S Pandey, R Brown, J Zhou, J Goonawardane, N Mishra, S Whittaker, C Mellan, T Marwal, R Datta, M Sengupta, S Ponnusamy, K Radhakrishnan, VS Abdullahi, A Charles, O Chattopadhyay, P Devi, P Caputo, D Peacock, T Wattal, C Goel, N Satwik, A Vaishya, R Agarwal, M Mavousian, A Lee, JH Bassi, J Silacci-Fegni, C Saliba, C Pinto, D Irie, T Yoshida, I Hamilton, WL Sato, K Bhatt, S Flaxman, S James, LC Corti, D Baker, S |
| author_sort | Mlcochova, P |
| collection | OXFORD |
| description | The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)<sup>1</sup>. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era. |
| first_indexed | 2024-03-07T07:05:51Z |
| format | Journal article |
| id | oxford-uuid:27a53bb0-8c1c-40de-887f-c3d017622294 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:05:51Z |
| publishDate | 2021 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:27a53bb0-8c1c-40de-887f-c3d0176222942022-05-03T12:55:40ZSARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:27a53bb0-8c1c-40de-887f-c3d017622294EnglishSymplectic ElementsSpringer Nature2021Mlcochova, PKemp, SADhar, MSPapa, GMeng, BFerreira, IATMDatir, RCollier, DAAlbecka, ASingh, SPandey, RBrown, JZhou, JGoonawardane, NMishra, SWhittaker, CMellan, TMarwal, RDatta, MSengupta, SPonnusamy, KRadhakrishnan, VSAbdullahi, ACharles, OChattopadhyay, PDevi, PCaputo, DPeacock, TWattal, CGoel, NSatwik, AVaishya, RAgarwal, MMavousian, ALee, JHBassi, JSilacci-Fegni, CSaliba, CPinto, DIrie, TYoshida, IHamilton, WLSato, KBhatt, SFlaxman, SJames, LCCorti, DBaker, SIndian SARS-CoV-2 Genomics Consortium (INSACOG)Genotype to Phenotype Japan (G2P-Japan) ConsortiumCITIID-NIHR BioResource COVID-19 CollaborationThe B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)<sup>1</sup>. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era. |
| spellingShingle | Mlcochova, P Kemp, SA Dhar, MS Papa, G Meng, B Ferreira, IATM Datir, R Collier, DA Albecka, A Singh, S Pandey, R Brown, J Zhou, J Goonawardane, N Mishra, S Whittaker, C Mellan, T Marwal, R Datta, M Sengupta, S Ponnusamy, K Radhakrishnan, VS Abdullahi, A Charles, O Chattopadhyay, P Devi, P Caputo, D Peacock, T Wattal, C Goel, N Satwik, A Vaishya, R Agarwal, M Mavousian, A Lee, JH Bassi, J Silacci-Fegni, C Saliba, C Pinto, D Irie, T Yoshida, I Hamilton, WL Sato, K Bhatt, S Flaxman, S James, LC Corti, D Baker, S SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion |
| title | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion |
| title_full | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion |
| title_fullStr | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion |
| title_full_unstemmed | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion |
| title_short | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion |
| title_sort | sars cov 2 b 1 617 2 delta variant replication and immune evasion |
| work_keys_str_mv | AT mlcochovap sarscov2b16172deltavariantreplicationandimmuneevasion AT kempsa sarscov2b16172deltavariantreplicationandimmuneevasion AT dharms sarscov2b16172deltavariantreplicationandimmuneevasion AT papag sarscov2b16172deltavariantreplicationandimmuneevasion AT mengb sarscov2b16172deltavariantreplicationandimmuneevasion AT ferreiraiatm sarscov2b16172deltavariantreplicationandimmuneevasion AT datirr sarscov2b16172deltavariantreplicationandimmuneevasion AT collierda sarscov2b16172deltavariantreplicationandimmuneevasion AT albeckaa sarscov2b16172deltavariantreplicationandimmuneevasion AT singhs sarscov2b16172deltavariantreplicationandimmuneevasion AT pandeyr sarscov2b16172deltavariantreplicationandimmuneevasion AT brownj sarscov2b16172deltavariantreplicationandimmuneevasion AT zhouj sarscov2b16172deltavariantreplicationandimmuneevasion AT goonawardanen sarscov2b16172deltavariantreplicationandimmuneevasion AT mishras sarscov2b16172deltavariantreplicationandimmuneevasion AT whittakerc sarscov2b16172deltavariantreplicationandimmuneevasion AT mellant sarscov2b16172deltavariantreplicationandimmuneevasion AT marwalr sarscov2b16172deltavariantreplicationandimmuneevasion AT dattam sarscov2b16172deltavariantreplicationandimmuneevasion AT senguptas sarscov2b16172deltavariantreplicationandimmuneevasion AT ponnusamyk sarscov2b16172deltavariantreplicationandimmuneevasion AT radhakrishnanvs sarscov2b16172deltavariantreplicationandimmuneevasion AT abdullahia sarscov2b16172deltavariantreplicationandimmuneevasion AT charleso sarscov2b16172deltavariantreplicationandimmuneevasion AT chattopadhyayp sarscov2b16172deltavariantreplicationandimmuneevasion AT devip sarscov2b16172deltavariantreplicationandimmuneevasion AT caputod sarscov2b16172deltavariantreplicationandimmuneevasion AT peacockt sarscov2b16172deltavariantreplicationandimmuneevasion AT wattalc sarscov2b16172deltavariantreplicationandimmuneevasion AT goeln sarscov2b16172deltavariantreplicationandimmuneevasion AT satwika sarscov2b16172deltavariantreplicationandimmuneevasion AT vaishyar sarscov2b16172deltavariantreplicationandimmuneevasion AT agarwalm sarscov2b16172deltavariantreplicationandimmuneevasion AT mavousiana sarscov2b16172deltavariantreplicationandimmuneevasion AT leejh sarscov2b16172deltavariantreplicationandimmuneevasion AT bassij sarscov2b16172deltavariantreplicationandimmuneevasion AT silaccifegnic sarscov2b16172deltavariantreplicationandimmuneevasion AT salibac sarscov2b16172deltavariantreplicationandimmuneevasion AT pintod sarscov2b16172deltavariantreplicationandimmuneevasion AT iriet sarscov2b16172deltavariantreplicationandimmuneevasion AT yoshidai sarscov2b16172deltavariantreplicationandimmuneevasion AT hamiltonwl sarscov2b16172deltavariantreplicationandimmuneevasion AT satok sarscov2b16172deltavariantreplicationandimmuneevasion AT bhatts sarscov2b16172deltavariantreplicationandimmuneevasion AT flaxmans sarscov2b16172deltavariantreplicationandimmuneevasion AT jameslc sarscov2b16172deltavariantreplicationandimmuneevasion AT cortid sarscov2b16172deltavariantreplicationandimmuneevasion AT bakers sarscov2b16172deltavariantreplicationandimmuneevasion |